Arizona sues L'Oreal over hair relaxer cancer
Analysis based on 16 articles · First reported Sep 11, 2026 · Last updated Sep 14, 2026
The lawsuit adds to L Oréal's mounting legal exposure from over 12,000 consolidated hair relaxer claims, raising the prospect of significant penalties, damages, and potential product restrictions that could weigh on its consumer products segment. Broader cosmetics and personal care peers such as Revlon face similar litigation risk, though the direct near-term market impact is likely limited given the company's size and the lengthy litigation timeline.
United States — Arizona Attorney General Kris Mayes filed a lawsuit in state court late Thursday against L Oréal, alleging the cosmetics company concealed evidence that its hair relaxer products could cause cancer in women. United States — Arizona is the first state to sue over alleged cancer risks linked to hair relaxers. The suit accuses L Oréal of violating state consumer protection laws by marketing products used predominantly by African American women without warning of alleged ovarian and uterine cancer risks. United States — Arizona seeks penalties, damages, and a court order forcing L Oréal to stop selling the products unless it warns of the cancer risk. The lawsuit follows a 2022 United States — National Institutes of Health study that found women using the products several times a year were more than twice as likely to develop uterine cancer. L Oréal faces more than 12,000 similar lawsuits consolidated in a Chicago federal court as multidistrict litigation, with trials possibly beginning next year. Revlon and other makers are also named in related suits. L Oréal maintains its products undergo rigorous safety reviews and that the claims lack legal or scientific merit.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard